Tenant Success Story: AstraZeneca completes acquisition of SixPeaks Bio (up to USD 300m)

We’re excited to share a major milestone from our community: AstraZeneca completed the acquisition of our tenant SixPeaks Bio AG (Basel) on 22 October 2025, with total consideration of up to USD 300 million (incl. upfront, deferred payment, and regulatory milestones). AstraZeneca+2S-GE+2

Main Body
What happened
AstraZeneca completed the acquisition of the remaining share capital of SixPeaks Bio AG on 22 October 2025 (via exercise of an option following an earlier investment). The deal structure disclosed in AstraZeneca’s reporting includes: AstraZeneca

• USD 170m paid on closing

• USD 30m payable after two years

• Up to USD 100m payable upon achieving certain regulatory milestones AstraZeneca

Why it matters
This is a strong signal for the Basel innovation ecosystem and a proud moment for our Tech Park Basel community: a tenant company’s science and execution have progressed to a global-scale outcome—validating the importance of early-stage infrastructure, talent, and partnerships in building breakthrough biotech. S-GE+1

About SixPeaks Bio (at a glance)
SixPeaks is working on next-generation weight-management approaches, with a focus on protecting/preserving lean (muscle) mass as a core component of healthier weight-loss solutions. AstraZeneca+2SixPeaks Bio+2
The company was founded in 2022 at Versant’s Ridgeline Discovery Engine in Basel (Basel Technology Park / today Tech Park Basel). SixPeaks Bio+1

Sources

• Startupticker: “AstraZeneca acquires SixPeaks for up to USD 300 million” (10 Nov 2025) Startupticker

• AstraZeneca: 9M and Q3 2025 results announcement (SixPeaks acquisition note) AstraZeneca

• Switzerland Global Enterprise: recap incl. “headquartered at Tech Park Basel” S-GE

• SixPeaks Bio website (mission/approach) SixPeaks Bio+2SixPeaks Bio+2